Pharmacological inhibition of the dipeptidyl peptidase-4 (DPP4) enzyme potentiates incretin action and is widely used to treat type 2 diabetes. Nevertheless, the precise cells and tissues critical for incretin degradation and glucose homeostasis remain unknown. Here, we use mouse genetics and pharmacologic DPP4 inhibition to identify DPP4 + cell types essential for incretin action. Although enterocyte DPP4 accounted for substantial intestinal DPP4 activity, ablation of enterocyte DPP4 in Dpp4
INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a metabolic disorder characterized by impaired insulin action and islet cell dysfunction (insufficient insulin and excess glucagon secretion) resulting in hyperglycemia. Among the newer antidiabetic agents used to treat subjects with T2DM, both glucagon-like peptide-1 receptor agonists (GLP-1RA) and dipeptidyl peptidase-4 inhibitors (DPP4i) potentiate gut hormone action (Campbell and Drucker, 2013; Drucker and Nauck, 2006; Inzucchi et al., 2012) . GLP1RAs are injectable, often peptide-based agents that circulate systemically and interact with a single, well-defined GLP-1R. In contrast, DPP4i are small molecule, orally ingested enzyme inhibitors that are better tolerated and, hence, more widely prescribed. Although the GLP-1R is the primary target for the glucoregulatory actions of GLP-1R agonists (Campbell and Drucker, 2013; Lamont et al., 2012; Smith et al., 2014; Tatarkiewicz et al., 2014) , the precise tissues, molecular targets, and signaling pathways critical for transducing the glucoregulatory actions of DPP4i remain incompletely understood.
DPP4 is a widely expressed exopeptidase that exists in two principal isoforms: a membrane-anchored enzyme containing a short intracellular tail and a soluble (sDPP4) circulating form; interestingly both isoforms display enzymatic activity (Mulvihill and Drucker, 2014) . DPP4 has over 40 identified substrates, however, the principal targets for glucoregulation are GLP-1 and glucosedependent insulinotropic polypeptide (GIP) (Flock et al., 2007; Hansotia et al., 2004; Mulvihill and Drucker, 2014; Omar and Ahré n, 2014) . Both GLP-1 and GIP are secreted from enteroendocrine cells at low basal rates in the fasting state and their plasma levels increase post-prandially. Circulating levels of intact, bioactive incretin hormones are extremely low due to rapid inactivation by DPP4 and renal clearance (Campbell and Drucker, 2013; Nauck and Meier, 2016; Sandoval and D'Alessio, 2015) .
Within the gut, three cell types are considered the principal sites of DPP4 expression and activity: enterocytes, cells of hematopoietic origin, and vascular endothelial cells (Hansen et al., 1999; Mulvihill and Drucker, 2014) . Notably, these cell types are all situated in proximity to enteroendocrine cells, rendering them highly suited anatomically for the DPP4-dependent control of peptide hormone degradation (Hansen et al., 1999) . As a result, the majority of GLP-1 and GIP is degraded rapidly following secretion, and the DPP-4-generated metabolites of GLP-1 and GIP are not high-affinity agonists for their classical receptors (Campbell and Drucker, 2013; Deacon et al., 1995; Hansen et al., 1999; Rolin et al., 2004) . Hence, whether the glucoregulatory actions of endogenous incretin hormones (legend continued on next page) are predominantly mediated via circulating intact peptides and classical endocrine mechanisms or through signals arising locally in the gut and propagated through neural and/or paracrine mechanisms remains unclear (Burcelin et al., 2014; Sandoval and D'Alessio, 2015; Waget et al., 2011) .
Experiments using low concentrations of DPP4i (that do not affect systemic DPP4 activity) have identified the gastrointestinal tract as a major site of action for the acute glucoregulatory actions of DPP4i in normoglycemic mice (Waget et al., 2011) . However, the precise cellular targets, within or beyond the gut, important for transducing the acute and chronic metabolic actions emanating from reduced DPP4 activity in normoglycemic or dysglycemic mice remain uncertain. To elucidate the importance of enterocyte versus endothelial versus bone marrowderived DPP4 for control of the enteroinsular axis, we generated and analyzed mice with: (1) elimination of Dpp4 in enterocytes (Dpp4 
RESULTS

Enteral Inhibition of DPP4 Is Sufficient to Regulate Glucose Metabolism in Chow-and High Fat Diet-Fed Wild-Type Mice
We first re-assessed previous observations linking intestinal selective sitagliptin treatment with improvement of oral glucose tolerance independent of changes in plasma DPP4 activity (Waget et al., 2011) . Although high dose sitagliptin (10 mg/kg body weight, referenced as systemic inhibition) robustly lowered plasma DPP4 activity ( Figure 1A ) and improved oral glucose tolerance ( Figure 1B ), selective enteral inhibition of DPP4 activity with low dose sitagliptin (14 mg/mouse, referenced as intestinalselective inhibition) significantly improved oral glucose tolerance ( Figure 1B ) without affecting plasma DPP4 activity ( Figure 1A ). In contrast to findings with systemic DPP4 inhibition, intestinal-selective inhibition of DPP4 activity with sitagliptin did not reduce glycemic excursion during an intraperitoneal glucose tolerance test (i.p. GTT) ( Figure 1C ). The glucoregulatory actions of intestinal-selective inhibition of DPP4 with sitagliptin were absent in mice lacking both the Glp1r and Gipr (double incretin receptor knockout [DIRKO]) ( Figure 1D ). Notably, intestinal-selective DPP4 inhibition with sitagliptin increased insulin levels (Figure 1E) , as well as plasma levels of intact GLP-1 and GIP (Figures 1F and 1G) . None of the concentrations of sitagliptin inhibited gastric emptying ( Figure S1 ). As previous studies assessed metabolic effects of intestinalselective DPP4 inhibition predominantly in normoglycemic mice (Waget et al., 2011) , we examined the actions of sitagliptin in high fat diet (HFD)-fed mice. Intestinal-selective DPP4 inhibition (14 mg/mouse) did not reduce plasma DPP4 activity in mice fed a HFD ( Figure 1H ). However, DPP4 activity in jejunal mucosa ( Figure 1I ) and in whole gut extracts from both the small and large bowel ( Figure 1J ) was reduced after intestinal-selective DPP4 inhibition with sitagliptin. Moreover, glycemic excursions were lower after an oral glucose challenge ( Figure 1K ), and plasma levels of insulin, active GLP-1, and active GIP were unchanged (versus control) after intestinal-selective DPP4 inhibition with sitagliptin ( Figures 1L-N) . In contrast, systemic inhibition of DPP4 with 10 mg/kg sitagliptin significantly increased circulating levels of insulin and active incretin hormones in HFD-fed mice ( Figures 1L-1N ).
Dpp4
Gut-/-Mice Exhibit Markedly Reduced Intestinal DPP4 Activity, but No Improvement in Glucose Tolerance To more precisely delineate the cellular target(s) of DPP4i within the gut, we generated mice with selective inactivation of Dpp4 in enterocytes (Dpp4 GutÀ/À ; Figure 2A ). Levels of Dpp4 mRNA transcripts in gut extracts and mucosa were 90% lower throughout the length of the intestine from Dpp4
GutÀ/À versus control VilCre mice, whereas Dpp4 expression in liver, kidney, and spleen was not reduced (Figures 2B and 2C) . Consistent with the RNA data, DPP4 enzyme activity was markedly reduced in gut extracts ( Figure 2D ) and mucosal scrapings ( Figure 2E ) from intestinal segments of Dpp4 GutÀ/À mice, whereas plasma DPP4 activity was not different compared to Vil-Cre controls (Figure 2F) . Surprisingly, despite marked reduction of intestinal mucosal DPP4 activity in Dpp4 GutÀ/À mice, oral glucose tolerance and insulin levels were unchanged (Figures 2G and 2H) . Plasma levels of active GLP-1 were not increased ( Figure 2I ), whereas the rise in post-prandial active GIP was reduced in Dpp4
GutÀ/À versus Vil-Cre control mice ( Figure 2J ). Furthermore, intestinal-selective DPP4 inhibition continued to produce a modest yet significant reduction in glycemic excursion after oral glucose administration in Dpp4 GutÀ/À (Figures 2K-2M), and both Dpp4 GutÀ/À and Vil-Cre control mice responded similarly to intestinal-selective DPP4 inhibition with equivalent increases in plasma insulin, active GLP-1, and active GIP levels ( Figures  S2A-S2C ). After 8 weeks of HFD feeding, Dpp4
GutÀ/À mice exhibited similar body weights and food intake compared to VilCre controls ( Figures S2D-S2F ). Consistent with findings in chow-fed Dpp4 GutÀ/À mice, oral glucose tolerance and insulin levels were similar between the two groups, and active levels of incretins were not preferentially increased following sitagliptin administration in HFD-fed Dpp4 GutÀ/À versus control mice ( Figures S2G-S2L ). Taken together, these findings reveal that (E-G) Plasma insulin (E), active GLP-1 (F), and active GIP (G) measured at 0 and 15 min after glucose challenge (45 min after sitagliptin/water gavage) during an OGTT in 10-to 12-week-old WT mice (n = 6-13/group).
(H) Plasma DPP4 activity 30 min after sitagliptin or water gavage in WT mice fed a HFD for 4 weeks (n = 5-15 mice/group). (I and J) DPP4 activity in mucosal scrapings or in extracts isolated from whole intestinal tissues from mice treated 30 min prior with 14 mg of sitagliptin (n = 7-9/ group). (K) Blood glucose taken 0-120 min after administration of oral glucose in 19-to 22-week-old WT mice fed a HFD for 4-6 weeks and treated with 14 mg/mouse or 10 mg/kg sitagliptin. Inset depicts iAUC analysis for glucose excursions (n = 16-17 mice/group).
(L-N) Plasma insulin (L), active GLP-1 (M), and active GIP (N) measured at 0 and 15 min after glucose gavage during an OGTT in HFD-fed WT mice (n = 5-11/ group). Data are presented as the mean ± SEM. *p % 0.05. (B and C) mRNA abundance of Dpp4 normalized to Ppia in whole extracts (B) of intestinal segments (Duo, duodenum; Jej, jejunum and ileum), liver (Liv), kidney (Kid), and spleen tissue or mucosal scrapings (C) of chow-fed 6-to 10-week-old female mice (n = 3-8/group). (D and E) DPP4 activity in extracts made from whole tissue (D) or mucosal scrapings (E) isolated from intestine, and whole extracts isolated from liver, kidney, and spleen (D) of chow-fed mice 6-to 10-week-old female mice (n = 3-8/group).
(F) Plasma DPP4 activity in Dpp4 GutÀ/À and Vil-cre control fed on chow diet.
(legend continued on next page) elimination of DPP4 in the gut epithelium targeted by Vil-Cre is not sufficient to recapitulate the metabolic phenotypes observed in Dpp4 À/À mice (Conarello et al., 2003; Marguet et al., 2000) (Flox Dpp4) in regard to plasma DPP4 activity, glucose tolerance, and plasma insulin and incretin hormone levels (Figures S3A-S3G ). These parameters were also similar in all three groups of mice after HFD feeding ( Figures S3H-S3N ). Therefore, we used Tie2-Cre mice as controls for all experiments. Dpp4 expression was reduced by 95% in sorted CD31 S4A-S4C ). Significant reductions in Dpp4 mRNA expression were also observed in tissues rich in endothelial cells including the aorta and lung ( Figure 3C ). Consistent with the expression of the Tie2 promoter in the hematopoietic cell lineage (Tang et al., 2010) , Dpp4 expression was reduced in CD45 + cells sorted from the lung ( Figure 3B ), as well as in the spleen ( Figure 3D ) and in bone marrow cells isolated from the femur and tibia ( Figure 3C ). In contrast, no changes in Dpp4 expression were detected in CD45 À CD31 À cells ( Figure 3B ). Deletion of endothelial and hematopoietic cell Dpp4 expression also accounted for a modest reduction in Dpp4 mRNA abundance in the liver of Dpp4 ECÀ/À mice ( Figure 3D ), and DPP4 activity was reduced in liver, kidney, and spleen of Dpp4 ECÀ/À mice compared to Tie2-Cre controls ( Figure 3E ). Both Dpp4 expression and DPP4 activity in whole gut tissue and mucosal scrapings were similar in Dpp4 Figure 3H ).
We next compared plasma DPP4 activity and plasma incretin levels in Dpp4
ECÀ/À (BMT), and control mice. In the fasting state, whole body disruption of the Dpp4 gene resulted in almost undetectable plasma DPP4 activity (Figure 3I) , as well as 10-fold and 3-fold elevations in fasting levels of active GLP-1 and GIP, respectively ( Figures 3J and 3K ). In contrast, Dpp4 ECÀ/À mice exhibited an $40%-50% reduction in plasma DPP4 activity ( Figure 3I As short-term administration of DPP4i may improve insulin sensitivity independent of marked changes in glycemia (Utzschneider et al., 2008) , we assessed insulin action in chow-fed, conscious, unrestrained control (Flox Dpp4 and Tie2-Cre) and Dpp4 ECÀ/À mice using the hyperinsulinemic (2.5 mU/kg/min) euglycemic clamp. Arterial glucose was clamped at similar levels in both groups ( Figure S6A ), and the glucose infusion rate (GIR) necessary to maintain euglycemia was not different between groups ( Figures S6B and S6C ). However, both basal and clamp insulin levels were higher in Dpp4 insulin-mediated suppression of endoR a (glucose appearance) was greater in Dpp4 ECÀ/À compared to control mice ( Figure S6E ). Conversely, despite higher clamped insulin levels, stimulation of R d (glucose disposal) was impaired in Dpp4 ECÀ/À compared to control mice ( Figures S6F-S6L ). Altogether, these data indicate that under a chow diet, Dpp4 ECÀ/À mice have no improvement in glucose tolerance and reduced insulin sensitivity in tissues utilizing glucose.
Chow-Fed Dpp4
EC-/-Mice Retain Glucoregulatory
Sensitivity to Sitagliptin
We next determined whether endothelial cell DPP4 is an important target for the glucoregulatory actions of sitagliptin. Consistent with data in WT mice ( Figure 1B ), Tie2-Cre mice exhibited a dose-dependent improvement in glucose tolerance following intestine-selective and systemic inhibition of DPP4 with sitagliptin ( Figures 4H and 4I ). This dose-dependent improvement in glucose tolerance in control mice was associated with increased levels of insulin, active GLP-1, and active GIP ( Figures 4K-4M ). In contrast, the differential glucoregulatory response to enteric versus systemic inhibition with sitagliptin was lost in Dpp4 ECÀ/À mice, with maximum glucose lowering achieved with the intestinal-selective dose of sitagliptin (Figures 4I and 4J) . Consistent with the glucose excursion data, both enteral and systemic DPP4 inhibition produced a further modest and similar augmentation of the already elevated levels of insulin, active GLP-1, and active GIP in Dpp4 ECÀ/À mice ( Figures 4K-4M) . Moreover, the already improved glucose tolerance ( Figure 4C ), in both Tie2-Cre(BMT) and Dpp4 ECÀ/À (BMT) mice (compared to Tie2-Cre and Dpp4 ECÀ/À mice, Figure 4B ), was not further affected by intestine-selective sitagliptin treatment ( Figures S6G-S6L ).
HFD-Fed Dpp4
EC-/-and Dpp4 EC-/-(BMT) Mice Are
Protected from Glucose Intolerance in the InsulinResistant State As previous studies have shown that whole body Dpp4 À/À mice are resistant to the deleterious metabolic effects of high fat feeding (Conarello et al., 2003) , and this is validated in Figure S7A , we analyzed Dpp4 ECÀ/À mice after 8 weeks of HFD feeding. No differences in body weight or food intake were observed in Dpp4 ECÀ/À and Dpp4 ECÀ/À (BMT) mice compared to their respective controls (Figures S7B-S7E).
As previously described in settings of weight gain (Lamers et al., 2011; Nagakura et al., 2003; Yang et al., 2014) , plasma DPP4 activity increased in all groups after HFD-feeding (Figure 1A versus 1H ), yet remained significantly lower in HFDfed Dpp4 ECÀ/À and Dpp4 ECÀ/À (BMT) mice compared with controls ( Figure 5A ). Dpp4 À/À mice demonstrated robust protection against glucose intolerance in response to HFD-feeding (Figure 5B) . Interestingly, in contrast to the lack of improvement in (BMT) showed a significant improvement in glucose tolerance compared to their respective controls ( Figures 5C and 5D) , and insulin levels were higher 15 min post-glucose administration ( Figure 5E ). Moreover, significant elevations in both active GLP-1 (3-fold) and active GIP (2.5-fold) were detected after oral glucose administration (Figures 5F and 5G) .
We next assessed insulin action in HFD-fed control and Dpp4 ECÀ/À mice. Arterial glucose was clamped at similar levels in HFD-fed control and Dpp4
ECÀ/À mice ( Figure S7F ). The GIR necessary to maintain euglycemia was not different between groups ( Figures S7G and S7H) . In contrast to findings under chow-fed conditions, clamp insulin levels were not higher in Dpp4 ECÀ/À mice ( Figure S7I ). Insulin-mediated suppression of endoR a was not significantly different between HFD-fed control and Dpp4 ECÀ/À mice ( Figure S7J ). The stimulation of R d in response to insulin was also not significantly different between groups ( Figure S7K ).
HFD-Feeding Extinguishes the Glucoregulatory Sensitivity to Low Dose Sitagliptin in Dpp4 EC-/-and
Dpp4
EC-/-(BMT) Mice We next assessed the effects of insulin resistance on intestinalselective DPP4 inhibition versus systemic DPP4 inhibition with sitagliptin treatment. Tie2-Cre control mice exhibited a proportional reduction in glycaemia to each dose of sitagliptin ( Figures  6A and 6C ). In contrast, intestinal-selective inhibition of DPP4 with sitagliptin had no effect on glucose tolerance in HFD-fed Dpp4 ECÀ/À mice whereas, systemic inhibition of DPP4 with sitagliptin improved glucose tolerance ( Figures 6B and 6C ). Consistent with findings in WT mice, Tie2-Cre control mice exhibited a significant increase in plasma levels of insulin and active GLP-1 only in response to systemic DPP4 inhibition; however, GIP was significantly elevated in response to both 14 mg of sitagliptin and systemic inhibition ( Figures 6D-6F ). Similarly, selective intestinal inhibition of DPP4 in Dpp4 ECÀ/À mice with sitagliptin did not augment levels of plasma insulin or active GLP-1 but did significantly increase active GIP levels ( Figures 6D-6F ). Increased plasma levels of insulin and active GLP-1 (but not active GIP) were detected following administration of the higher systemic dose of sitagliptin in Dpp4 ECÀ/À mice ( Figures 6D-6F ). Following bone marrow transplantation, control mice (Tie2-Cre (BMT)) also exhibited dose-dependent reductions in glucose excursions in response to sitagliptin administration (Figures 6G and 6I) . Consistent with findings in the absence of bone marrow transplantation, high fat fed Dpp4 ECÀ/À (BMT) mice did not exhibit a glucoregulatory response to intestine-selective inhibition of DPP4 with sitagliptin but retained responsivity to systemic DPP4 inhibition (Figures 6H and 6I) . No differences in insulin levels were noted between genotypes or sitagliptin doses (Figure 6J) ; however, Dpp4 ECÀ/À (BMT) mice had elevated levels of plasma active GLP-1 and GIP after oral glucose administration, in the absence of sitagliptin ( Figures 6K and 6L ).
DISCUSSION
Incretin hormones (i.e., GIP and GLP-1) are secreted by enteroendocrine K-and L-cells, in response to food ingestion to promote efficient nutrient disposal. The development of DPP4i was based on a classical paradigm linking systemic reduction of plasma DPP4 activity with increased circulating levels of active GLP-1 and GIP, which in turn, augment insulin and inhibit glucagon secretion and lower glucose (Deacon, 2004; Drucker, 2007; Omar and Ahré n, 2014) . However, circulating levels of incretin hormones are extremely low and as little as 10% of intact bioactive GLP-1 secreted by L-cells actually reaches the pancreas (Hansen et al., 1999; Hjøllund et al., 2011) . Furthermore, administration of a low dose of DPP4i to selectively inhibit DPP4 activity locally within the intestine is sufficient to improve glucose tolerance (Omar and Ahré n, 2014; Waget et al., 2011) . These findings highlight the importance of a local, intestinal DPP4-sensitive enteroinsular axis for the control of glucose homeostasis. Nevertheless, the precise DPP4 + cell types within the gut responsible for these DPP4-dependent glucoregulatory actions have not been identified.
Enteric Inhibition of DPP4 by Sitagliptin Significantly Improves Glucose Tolerance in Chow-Fed and HFDFed Mice
We now reproduce the findings of Waget et al. (2011) that local intestinal DPP4 inhibition improves oral glucose tolerance in WT mice. Importantly, we extend these observations by demonstrating that the glucoregulatory actions of enteric DPP4 inhibition are completely extinguished in DIRKO mice, thereby reaffirming a dominant role for activation of both incretin receptors in the glycemic response to DPP4 inhibition (Flock et al., 2007; Hansotia et al., 2004) . Interestingly, intestinal selective DPP4 inhibition with sitagliptin was sufficient to augment circulating levels of insulin, active GLP-1 and active GIP under chow diet-fed conditions, despite no inhibition of systemic DPP4 activity. In contrast, in HFD-fed WT mice, intestinal-selective inhibition of DPP4 with sitagliptin improved glucose excursion by over 50% without a detectable increase in plasma levels of insulin, active GLP-1 and active GIP, highlighting the importance of local, enteral-portal incretin gradients (Nakajima et al., 2015; Waget et al., 2011) in the control of glucose homeostasis under these conditions. We then sought to identify the cellular origin of DPP4 within the gastrointestinal tract critical for glucoregulation and, as such, genetically eliminated Dpp4 in enterocytes, endothelial cells, and immune cells. 
DPP4 Expressed in Villin
+ Enterocytes Does Not Contribute to Incretin Cleavage or Glucoregulation Although enterocytes within the mucosal epithelium account for 85%-90% of total DPP4 expression in the gut, our data show that DPP4 activity in villin + epithelial cells does not contribute significantly to circulating DPP4 activity and does not play an important role in the cleavage of GLP-1 and GIP. Importantly, although intestine-selective inhibition of DPP4 with sitagliptin potently reduced DPP4 activity in gut mucosal extracts (that contain predominantly enterocytes), genetic elimination of Dpp4 in Dpp4 GutÀ/À mice had no effect on basal glucose tolerance and did not abrogate the glucoregulatory effects of intestinal-selective DPP4 inhibition under regular chow or HFD conditions. Hence, the principal DPP4 + cell type within the small bowel, the enterocyte, does not substantially contribute to DPP4-mediated control of glucose homeostasis.
Genetic Elimination of DPP4 in Tie2
+ Cells Reveals Cellular Origin of DPP4 Responsible for Incretin Cleavage In contrast to findings in Dpp4 GutÀ/À mice, DPP4 activity in the intestine of Dpp4 ECÀ/À mice was not reduced following genetic elimination of DPP4 in vascular endothelial cells and cells of hematopoietic origin. Nevertheless, our study revealed important contributions from endothelial cells and bone marrow-derived cells to total plasma DPP4 activity ( Figure 3I ). Targeting DPP4 deletion in endothelial cells decreased DPP4 activity by $25%, and bone marrow transplantation studies revealed a further contribution of hematopoietic cells to total plasma DPP4 activity, in keeping with findings reported by others (Wang et al., 2014) . Consistent with the immunohistochemical localization of DPP4 in capillary endothelium adjacent to GLP-1 secreting enteroendocrine cells (Hansen et al., 1999) , our genetic data demonstrated that endothelial cell DPP4 is responsible for inactivation of GLP-1 and GIP in the post-prandial state under both chowand HFD-fed conditions. Although DPP4 is widely expressed in cells of hematopoietic origin, previous studies have not revealed a role for bone marrow-derived cells in the control of incretin inactivation. Unexpectedly, fasting plasma levels of intact GIP were reduced in Dpp4 ECÀ/À mice after bone marrow transplantation. These findings suggest a heretofore unappreciated role for one or more hematopoietic cell lineages in the DPP4-mediated inactivation of GIP (Table S1 ). Nevertheless, despite a contribution of bone marrow-derived cells to plasma DPP4 activity, Dpp4 ECÀ/À and Dpp4 ECÀ/À (BMT) mice displayed similar increased levels of fasting and post-prandial active GLP-1 under both regular chow-and HFD-fed conditions. Hence, DPP4 + endothelial cells, but not bone marrow-derived cells, are critical for control of GLP-1 inactivation. These findings highlight the utility of mouse genetics for elucidating novel cellular determinants of DPP4-dependent incretin hormone degradation.
Dietary Induction of Insulin Resistance Reveals Important Roles of DPP4 in Endothelial Cells for
Glucoregulation Surprisingly, despite increased circulating levels of intact incretin hormones and an augmented insulin response to glucose, regular chow-fed Dpp4 ECÀ/À mice did not exhibit improved glucose tolerance. These data highlight the potential importance of local incretin signaling gradients rather than illustrate a clear endocrine mechanism for the glucoregulation mediated by DPP4 inhibition. To more comprehensively address glucose disposal and insulin sensitivity, we performed hyperinsulinemic-euglycemic clamps. Compared to controls, Dpp4 ECÀ/À mice had significantly decreased glucose disposal complemented by a decrease in glucose production, resulting in no overall change in the glucose infusion rate. These data are consistent with our previous studies demonstrating that genetic elimination of the Glp1r increased muscle glucose uptake but reduced hepatic insulin sensitivity (Ayala et al., 2010) . Nevertheless, low dose sitagliptin remained effective in lowering glycemic excursions after oral glucose in Dpp4 ECÀ/À mice. Hence, under the experimental conditions in regular chow-fed mice described here, the target(s) of selective intestinal inhibition of DPP4 remains unknown. Unexpectedly, in contrast to the lack of a glucoregulatory phenotype on a regular chow diet, both Dpp4 ECÀ/À and
Dpp4
ECÀ/À (BMT) mice exhibited significantly improved glucose tolerance under high fat diet conditions. Further evidence for the contribution of endothelial cell DPP4 to DPP4i-mediated glucoregulation was revealed by the lack of response of both Dpp4 ECÀ/À and Dpp4 ECÀ/À (BMT) high fat diet-fed mice to intestinal-selective DPP4 inhibition with low dose sitagliptin. In contrast, the response to systemic inhibition of DPP4 activity with high dose sitagliptin remained intact in Dpp4 ECÀ/À and
ECÀ/À (BMT) mice. High fat feeding has significant effects on many aspects of the enteroinsular axis, and discerning the biological importance of endothelial cell DPP4 under conditions of insulin resistance requires further investigations.
Resistance to Diet-Induced Obesity in Dpp4
-/-Mice Is Not Recapitulated by Targeting DPP4 Activity in Enterocytes, Endothelial Cells, or Hematopoietic Cells Although whole body germline inactivation of the Dpp4 gene was associated with resistance to diet-induced obesity ( Figure S7 ) (Conarello et al., 2003) , the majority of diabetic humans treated with DPP4i do not exhibit weight loss (Deacon, 2011) . Furthermore, despite significant reductions in plasma DPP4 activity in regular chow-and HFD-fed Dpp4 ECÀ/À mice, no changes in body weight or food intake were observed. Hence, despite endothelial cell DPP4 accounting for $50% of DPP4-mediated inactivation of GLP-1, the increased plasma GLP-1 levels detected in HFD-fed Dpp4 ECÀ/À and Dpp4 ECÀ/À (BMT) mice were not sufficient to control body weight. These findings highlight the importance of DPP4 activity in cell types beyond ECs, as well as other DPP4 substrates that also regulate glucose metabolism and food intake (Mulvihill and Drucker, 2014) , in the integrated metabolic response to genetic or pharmacological DPP4 inhibition.
In summary, we reveal that (1) enterocyte-derived DPP4 does not contribute to plasma DPP4 activity or regulate incretin degradation, and (2) inhibition of enterocyte DPP4 does not mediate the glucoregulatory properties of intestinal-selective DPP4 inhibition. DPP4 in hematopoietic cells: (1) contributes to plasma DPP4 activity, (2) selectively cleaves GIP but not GLP-1, and (3) does not contribute to glucose control. Finally, endothelial DPP4: (1) contributes to plasma DPP4 activity, (2) is responsible for degradation of both GIP and GLP-1, and (3) is the target of gut-selective inhibition of DPP4 by sitagliptin under conditions of insulin resistance and metabolic stress (Figure 7) . Interestingly, systemic DPP4 inhibition maintained glucoselowering effects, despite genetic elimination of DPP4 within endothelial cells. This is in accordance with only partial metabolic improvement in Dpp4 ECÀ/À mice compared with the whole body Dpp4 À/À mice and suggests that DPP4 expression in other tissues remains critical for glucoregulation in the context of systemic DPP4 inhibition. Although treatment with DPP4i is generally well tolerated, rare adverse events including arthralgia, rhinitis, skin rash, pancreatitis, and hospitalization for heart failure have been described (Deacon, 2011; Mulvihill and Drucker, 2014) . Our findings identify the importance of specific DPP4 + cell types for incretin degradation and glucose control under different metabolic conditions, thereby enabling targeted development of DPP4i for compartment-selective potentiation of incretin action.
EXPERIMENTAL PROCEDURES Animals
Mice were housed under a 12-hr light/dark cycle in the Toronto Centre for Phenogenomics and maintained on regular chow (2018, 18% kcal from fat; Harlan Teklad) or HFD (45% kcal fat, 35% kcal carbohydrate, 0.05% wt/wt cholesterol, D12451, Research Diets) with free access to food and water, unless otherwise noted. Dpp4 À/À mice were re-derived from a colony described previously (Marguet et al., 2000; Sauvé et al., 2010) . Double incretin receptor knockout mice (DIRKO) were previously described (Hansotia et al., 2004 (Hansotia et al., , 2007 ). Whenever possible, we carried out experiments in all four groups of mice ( Figure S3 ). However, due to lack of phenotypic differences in the control lines, we present data for mice expressing Cre and mice with the two different targeted Dpp4 deletions. All mice were born at the expected Mendelian ratios and appeared healthy. All experiments used age-and sex-matched littermates. Mice were fasted for 5 hr prior to metabolic studies. All experiments were approved by the Animal Care and Use Subcommittee at the Toronto Centre for Phenogenomics, Mt. Sinai Hospital.
Oral and Intraperitoneal Glucose Tolerance Tests
After a 5-hr fast, mice were administered water or sitagliptin (Merck Laboratories) at 14 mg/mouse (intestinal-specific dose) or 10 mg/kg (systemic inhibition) by gavage; 30 min later regular chow-fed mice were gavaged or i.p.-injected with 20% glucose in PBS (2 g/kg of body weight). HFD-fed mice were gavaged with 50% glucose in PBS (2 g/kg of body weight). Blood for glucose measurements (Contour glucometer, Bayer Healthcare) was taken up to 120 min post-injection. Glucose tolerance was assessed using the incremental AUC glucose (iAUC). For gastric emptying, 1% acetaminophen was administered and blood samples were taken for measurement of acetaminophen (Flock et al., 2011 ).
Blood and Tissue Collection
Blood was taken via the tail vein during metabolic studies. For terminal studies, mice were sacrificed by CO 2 inhalation, blood was obtained by cardiac puncture. Mucosal scrapings were isolated by opening the intestine and using a surgical blade to remove the mucosal layer. Blood was collected in heparin-coated capillary microvette tubes for assessment of DPP4 activity using a fluorometric assay (substrate: 10 mM H-Gly-Pro-AMC HBr [Bachem #I-1225], standard: AMC [Bachem #Q-1025]). For measurement of active GLP-1 (Mesoscale 150JVC-1), active GIP (Crystal Chem), glucagon (Mercodia), and insulin (ultrasensitive insulin ELISA, Alpco Diagnostics) blood was mixed with 10% TED (5,000 KIU/mL Trasylol, 1.2 mg/mL EDTA, and 0.1 nmol/L Diprotin A) and plasma stored at À80 C until the assay was performed.
Bone Marrow Transplantation
Bone marrow chimeras were generated by irradiating Dpp4 ECÀ/À and Tie2-cre CD45.2 + recipient male mice (1,100 cGy, split into two equal doses 4 hr apart)
followed by tail vein injection of 5 3 10 6 congenic bone marrow cells from WT B6.SJL-Ptprca Pepcb/BoyJ CD45.1 + male donor mice (obtained from Jackson Labs), as described (Yusta et al., 2015) . After 10 weeks, the efficiency of reconstitution was assessed by flow cytometric (Gallios, Beckman Coulter) analysis of blood with CD45.1-PE-Cy5.5 and CD45.2-APC-Cy7 antibodies.
Flow Cytometry for Isolation of CD45+ and CD31+ Cells
Mice were fasted for 2 hr, injected with 25 U of heparin intramuscularly, and anesthetized with Avertin. Ice-cold DMEM was perfused through the right ventricle, and the lung was then injected with 1.5 mg of ice-cold collagenase. The lung was digested for 45 min at 37 C under constant agitation in DMEM containing collagenase type A 1.5 mg\mL, glucose 2 mg\mL, and DNase I 30 U\mL after which 25 mL of PBS containing 10% FBS was added. Lungs were pooled from two mice. Cells were strained by 40 mM strainer and isolated by centrifugation. Red blood cells were lysed using red blood lysis solution (BioLegend) and resuspended in PBS containing 2 mM EDTA, 25 mM HEPES, and 2% FCS after isolation. 
Food Intake
For calculation of food intake, mice were placed in individual cages with measured amounts of food and bedding for 72 hr.
Gene Expression
First-strand cDNA was synthesized from total RNA using the SuperScript III synthesis system (Invitrogen). Tissue mRNA levels were determined using a two-step quantitative real-time PCR protocol on an ABI Prism (model 7900 HT) Sequence Detection System (Applied Biosystems) according to the manufacturer's instructions. Primer probe sets were manufactured by TaqMan Assays-on-Demand (Applied Biosystems). The standard curve method was used to determine mRNA concentrations, and each gene was normalized to cyclophilin (Ppia) expression.
Hyperinsulinemic-Euglycemic Clamps
Flox Dpp4, Tie2-Cre, and Dpp4 ECÀ/À mice on chow or high fat diets were catheterized for at least 5 days before experimentation and clamped as described previously (Ayala et al., 2008 ) with some modifications as described below. Briefly, hyperinsulinemic-euglycemic clamps were performed on 5-hr fasted mice. A 2.5-mCi bolus of [3-3 H]glucose was given at t = À90 min before insulin infusion, followed by a 0.04 mCi/min infusion for 90 min. Blood was obtained via an arterial catheter. Basal glucose-specific activity was determined from blood samples taken at t = À15 and À5 min. Fasting insulin levels were determined from samples taken at t = À5 min. The clamp was begun at t = 0 min with a continuous infusion of human insulin (2.5 mU/kg/min, Humulin R; Eli Lilly). Blood glucose samples were taken every 10 min starting at t = 0 min. A variable glucose infusion containing 50% dextrose spiked with [3-3 H]glucose (0.06 mCi/mL) was administered to maintain euglycemia ($150-160 mg/dL). Mice received saline-washed erythrocytes from donors throughout the clamp (5-6 mL/min). Blood samples (80-240 mL) were taken every 10 min from t = 80 to 120 min and processed to determine plasma [3-3 H]glucose. Clamp insulin was determined at t = 100 and 120 min. At t = 120 min, mice were anesthetized with sodium pentobarbital. Glucose appearance (R a ) and disappearance (R d ) were analyzed using Steele non-steady-state equations. Endogenous glucose production (endoR a ) was calculated by subtracting the glucose infusion rate from total R a. (Ayala et al., 2008) .
Statistical Methods
Results are expressed as the mean ± SEM. Statistical comparisons were made by one-or two-way ANOVA followed by Tukey post hoc or by Student's t test (only two conditions) using GraphPad Prism 5. Statistically significant differences are indicated as *p % 0.05. Lamers, D., Famulla, S., Wronkowitz, N., Hartwig, S., Lehr, S., Ouwens, D.M., Eckardt, K., Kaufman, J.M., Ryden, M., M€ uller, S., et al. (2011) . Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes 60, 1917 -1925 . Lamont, B.J., Li, Y., Kwan, E., Brown, T.J., Gaisano, H., and Drucker, D.J. (2012 . Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. J. Clin. Invest. 122, [388] [389] [390] [391] [392] [393] [394] [395] [396] [397] [398] [399] [400] [401] [402] Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.M., Pierres, M., Nielsen, P.F., Ribel, U., Watanabe, T., Drucker, D.J., and Wagtmann, N. (2000) . Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc. Natl. Acad. Sci. USA 97, 6874-6879.
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